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Short title: CARD14 mutation in mice drives psoriasiform disease 
 
ABSTRACT: 
Rare autosomal dominant mutations in the gene encoding the keratinocyte signaling molecule, 
Caspase Recruitment Domain-Containing Protein 14 (CARD14), have been associated with 
an increased susceptibility to psoriasis but the physiological impact of CARD14 gain-of-
function mutations remains to be fully determined in vivo. Here, we report that heterozygous 
mice harboring a CARD14 gain-of-function mutation (Card14∆E138) spontaneously develop 
a chronic psoriatic phenotype with characteristic scaling skin lesions, epidermal thickening, 
keratinocyte hyperproliferation, hyperkeratosis and immune cell infiltration. Affected skin of 
these mice is characterized by elevated expression of anti-microbial peptides, chemokines and 
cytokines (including Th17 cell-signature cytokines), and an immune infiltrate rich in 
neutrophils, myeloid cells and T-cells, reminiscent of human psoriatic skin. Disease 
pathogenesis was driven by the IL-23/IL-17 axis and neutralization of IL-23p19, the key 
cytokine in maintaining Th17 cell polarization, significantly reduced skin lesions and the 
expression of antimicrobial peptides and pro-inflammatory cytokines. Therefore, 
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hyperactivation of CARD14 alone is sufficient to orchestrate the complex 
immunopathogenesis that drives Th17-mediated psoriasis skin disease in vivo.  
 
INTRODUCTION: 
Psoriasis is a common chronic inflammatory disease of the skin that is estimated to affect 
approximately 2% of the global population, and is equally prevalent in males and females 
(Christophers 2001, Gudjonsson and Elder 2007). Psoriasis is characterized by scaly 
erythematous plaques on the skin, which given its chronic course significantly impairs the 
quality of life of affected individuals. The most common form of psoriasis is psoriasis 
vulgaris (plaque psoriasis) but other forms exist with distinct clinical features, including 
guttate psoriasis, pustular psoriasis and palmoplantar psoriasis (Griffiths and Barker 2007). 20 
- 30% of plaque psoriasis cases are associated with debilitating psoriatic arthritis and psoriasis 
patients can suffer from comorbidities including cardiovascular disease, diabetes and obesity 
(Griffiths and Barker 2007, Mease et al., 2013). Histological hallmarks of psoriasis include 
epidermal acanthosis, keratinocyte hyperproliferation, hyperkeratosis, cutaneous immune cell 
infiltration and angiogenesis. Disease symptoms arise from a complex interaction between 
keratinocytes and infiltrating immune cells (Bos and De Rie 1999, Boyman et al., 2007, Sano 
et al., 2005, Valdimarsson et al., 1995). However, the early triggers that lead to full-blown 
disease are not well understood, confounded by the wide range of genetic factors that 
contribute to an elevated risk of developing psoriasis, including genes controlling epidermal 
barrier integrity (e.g. LCE3B, LCE3D), antigen presentation (e.g. HLA-Cw*0602, ERAP1), 
and genes of the innate (e.g. NFKBIA) and adaptive immune system (e.g. IL12B, IL23R) (Tsoi 
et al., 2012). Interestingly, while genome-wide association studies have revealed that more 
than 80 genes in Caucasian and Han Chinese populations are associated with an increased 
susceptibility to psoriasis, very few genetic variants have actually been studied in vivo (Sheng 
et al., 2014, Tsoi et al., 2017). 
Rare autosomal dominant mutations in the gene encoding a keratinocyte scaffold 
molecule, CARD14 (which maps to the Psoriasis susceptibility locus 2 (PSORS2)) have been 
associated with a number of psoriatic phenotypes including plaque psoriasis and psoriatic 
arthritis, generalized pustular psoriasis, palmoplantar pustular psoriasis, in addition to familial 
and sporadic cases of the clinically related but rare disease, pityriasis rubra pilaris (PRP) 
(Fuchs-Telem et al., 2012, Has et al., 2016, Hong et al., 2014, Jordan et al., 2012, Jordan et 
al., 2012, Li et al., 2015, Mossner et al., 2015, Sugiura et al., 2014, Takeichi et al., 2017, 
Takeichi et al., 2017). CARD14 is a pro-inflammatory signaling molecule, whose expression 
is predominantly restricted to the placenta and keratinocytes of the skin though interestingly, 
CARD14 expression was also reported on CD31-positive endothelial cells (Fuchs-Telem 
2012) (Harden et al., 2014). CARD14 is the second member of the CARD/ membrane-
associated guanylate kinase (MAGUK)-domain (CARMA) protein family (Bertin et al., 2001, 
Scudiero et al., 2014). CARMA proteins contain CARD, coiled-coil, SH3 and guanylate 
kinase-like domains and they exist in an auto-inhibitory state. In response to external stimuli 
CARMA proteins are phosphorylated via Protein Kinase C isoforms (Scudiero 2014). 
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Subsequently, they undergo a conformational change, facilitating recruitment of the 
interacting partners Bcl10 (via CARD: CARD domain interactions) and Malt1 to form the 
CARMA: Bcl10:Malt1 (CBM) signaling complex, or “signalosome” (Bertin 2001, Gaide et 
al., 2001, Howes et al., 2016, Jattani et al., 2016, McAllister-Lucas et al., 2001, Scudiero 
2014). CARD11 (CARMA1) expressed in lymphoid cells, is activated upon B- and T-cell 
receptor engagement and gain-of-function (GoF) mutations in the genes encoding CARD11, 
Bcl10 and Malt1 have been associated with a number of lymphoid malignancies (Gaide et al., 
2002, Juilland and Thome 2016, Pomerantz et al., 2002, Wang et al., 2002). Similarly, 
CARD10 (CARMA3), expressed in epithelial tissue and activated by G protein-coupled 
receptor stimulation, has been linked to the progression of various carcinomas (Du et al., 
2014, Pan et al., 2016, Xia et al., 2016, Xie et al., 2014). 
CARD14 was recently described to be activated in vitro in response to zymosan and 
Staphylococcus aureus pathogen-associated molecular pattern agonists (Schmitt et al., 2016, 
Scudiero et al., 2017). Therefore, CARD14 likely plays its main role in innate immune 
defense, which is supported by the genes activated downstream of CARD14, which typically 
encode for pro-inflammatory cytokines and chemokines, including IL-36γ, IL-8 and Ccl20 
(Jordan 2012). The contribution of CARD14 gain-of-function to psoriatic disease 
pathogenesis, however, remains unclear. CARD14 mutations are rare and some 
polymorphisms (p.Arg820Trp, p.Arg547Ser) associated with PRP in a Taiwanese study were 
also shown to be present in the general population (Hong 2014). Other polymorphisms 
(p.Gly117Ser) have shown phenotypes that vary considerably, with respect to age of onset 
and severity, raising the possibility that other genetic or environmental factors may be 
required (Jordan 2012).  
Mutation or deletion of a single glutamic acid (E138) in the coiled-coil domain of 
CARD14 has been associated with both psoriasis and PRP (Fuchs-Telem 2012, Has 2016, 
Inoue et al., 2016, Jordan 2012). These variants resulted in severe phenotypes and add support 
to the relevance of CARD14 mutations to an increased risk of psoriatic skin disease. 
However, the contribution of CARD14 to psoriasis pathogenesis remains open and therefore 
we sought to determine the functional impact of CARD14 E138 mutation in vivo.  
 
RESULTS: 
CARD14 gain-of-function mutation cause spontaneous signalosome formation in 
primary human keratinocytes which is dependent on a functional CARD domain 
Consistent with previous reports, CARD14 E138A and ∆E138 mutants both caused enhanced 
NF-κB and AP-1 activation in vitro in HEK293 cells compared to wild-type (WT) CARD14, 
with the E138A mutant showing a more potent response (Supplementary Fig. 1a) (Afonina 
et al., 2016, Scudiero et al., 2011). CARD14 E138A and CARD14 ∆E138 GoF mutants were 
also overexpressed in primary keratinocytes and HEK293 cells and were observed to interact 
with endogenous Bcl10 by co-immunoprecipitation (Fig. 1a, Supplementary Fig. 1b), 
whereas Bcl10 interaction with CARD14 WT was below detectable levels. As this was 
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contrary to previous findings (Afonina 2016, Scudiero 2011), we sought to assess other means 
of CARD14 activity. Interestingly, there was a reduction of Bcl10 expression observed in the 
presence of all three CARD14 constructs in HEK293 cells (Supplementary Fig. 1b) and a 
decrease of CARD14 mutant expression in primary keratinocytes (Fig. 1a). Previously, it has 
been suggested that CARD14 mutants associated with psoriasis are less soluble than wild-
type CARD14 (Berki et al., 2015). Additionally, it has been previously described that Bcl10 
forms oligomeric structures that can be nucleated by CARD11 (Qiao et al., 2013). It was 
therefore of interest to determine whether interaction of CARD14 with Bcl10 can induce 
nucleation and insolubility of the latter. First it was assessed whether mutation of the 
CARD14 CARD domain could diminish downstream effects. The CARD14 R38 residue has 
been previously described to be at the Bcl10 interacting interface and substitution of arginine 
R38 with cysteine in the CARD domain was previously reported to lack the ability to activate 
NF-κB (Jordan 2012, Qiao 2013) so it was anticpiated that the R38C mutation would abolish 
CARD:CARD interactions. Indeed, mutation of the R38 residue in the CARD14 E138A 
construct completely abrogates the ability of the E138A mutant to interact with Bcl10 
(Supplementary Fig. 1c) and to potently activate NF-κB and AP-1 in HEK293 cells 
(Supplementary Fig. 1d). R38C mutation also diminished the ability of CARD14 E138A to 
drive IL-8 production in primary keratinocytes (Supplementary Fig. 1e). 
To assess nucleation of Bcl10 in the presence of CARD14 GoF mutants, primary 
keratinocytes were transfected with CARD14 WT, CARD14 E138A and CARD14 
R38C/E138A. Cells were lysed in Triton X-100-containing buffer and Triton-insoluble and 
soluble fractions were assessed by SDS-PAGE. As expected, mutant CARD14 variants were 
found at higher levels in the insoluble fraction than wild-type CARD14. Moreover, levels of  
Bcl10 were more highly increased in the insoluble fraction in the presence of CARD14 
E138A compared to CARD14 WT, and this was dependent on a functional CARD domain 
(Fig. 1c).  
Insoluble mutant CARD14 E138A and CARD14 ∆E138/Bcl10 complexes or “signalosomes” 
are visible by confocal microscopy in primary keratinocytes (Fig. 1d), while CARD14 WT 
was more widely expressed throughout the cytoplasm, consistent with its weak interaction 
with Bcl10 in co-immunoprecipitation studies. Interestingly, CARD14 R38C/E138A retained 
the ability to form insoluble oligomers (Fig. 1c, d), but it failed to recruit Bcl10 to these 
complexes in primary keratinocytes (Fig. 1d). 
Spontaneous signalosome formation induced by CARD14 E138A and CARD14 ∆E138 
resulted in enhanced Malt1 para-caspase activity in HEK293 cells, as measured using a 
previously described fluorescence resonance energy transfer (FRET)-based assay (Pelzer et 
al., 2013) (Fig. 1e), consistent with previous reports (Afonina 2016, Howes 2016). Malt1 
displayed augmented catalytic activity in the presence of CARD14 E138A and CARD14 
∆E138 mutants compared to WT (Fig. 1e). However, CARD14 R38C/E138A lost the ability 
to stimulate Malt1 activity beyond basal levels. In primary keratinocytes, CARD14 E138A 
and CARD14 ∆E138 mutants drive production of IL-36γ, however, again disruption of the 
CARD domain abolishes this effect (Fig. 1f). 
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Mutation of Card14 E138 causes spontaneous psoriasiform disease in mice 
To define the physiological impact of CARD14 E138 gain-of-function mutation in potentially 
driving psoriasis pathogenesis, a transgenic mouse incorporating a deletion of the E138 
residue of CARD14 was generated using CRISPR/Cas9 technology (Supplementary Fig. 2a, 
b). The Card14∆E138 mutation was chosen as it displayed less potent activation of NF-κB 
and it was speculated that these mice might be less likely to suffer unwanted defects due to 
hyperactive NF-κB activity. Card14∆E138 heterozygous mice appeared indistinguishable 
from wild-type littermates at birth (Supplementary Fig. 2c), but developed dry flaky skin 
patches on the back at 5 days of age, which begins to disappear at 7 days. However, this 
progresses to the development of thickened squamous skin on the tail (between 2- 3 weeks) 
and finally the ears (at 4- 5 weeks), reminiscent of human psoriasis skin lesions 
(Supplementary Fig. 2d, e). Adult mice showed a chronic psoriatic phenotype with 
thickened squamous skin of the ears and tail, and dry skin around the eyes and whiskers, 
affecting 100% of heterozygous male and female mice (Fig. 2a). Ear thickness was 
significantly increased in Card14∆E138+/– mice compared to wild-type littermates (Fig. 2b). 
There was no significant difference in weight in Card14∆E138+/– adult mice compared to 
wild-type littermates (Fig. 2c). 
Hematoxylin and eosin (H&E) staining of ear tissue from Card14∆E138+/– mice 
revealed acanthosis due to keratinocyte hyperproliferation and immune cell infiltration of the 
skin (Fig. 2d), areas of hyperkeratosis (Fig. 2e), including parakeratosis (arrow) and 
orthokeratosis (arrowhead), and keratotic follicular plugging (Supplementary Fig. 3a), all 
hallmarks of human psoriatic skin disease. Similarly, tail skin showed marked hyperplasia 
(Supplementary Fig. 3b) with increased thickening of the epidermis and immune cell 
infiltration. In addition to a clear increase in infiltrate of immune cells, the presence of 
microabscesses was also observed in the epidermis of Card14∆E138+/– mice (Fig. 2f). 
Positive staining with the neutrophil marker, Ly6G, indicated that neutrophils make up the 
composition of these microabscesses (Fig. 2g). An increased number of enlarged CD31-
positive blood vessels were also histologically observed in the dermis, indicating an increase 
in the dermal vasculature in psoriatic tissue from Card14∆E138+/– mice (Fig. 2h, 
Supplementary Fig. 3c). In Card14∆E138+/–mice, basal keratinocytes showed strong and 
abundant expression of the proliferation marker Ki67, indicating hyperproliferation of 
keratinocytes in the basal layer (Fig. 2i, Supplementary Fig. 3d). Similarly, Keratin-14 
expression, a marker for the proliferative basal layer of the epidermis, was no longer restricted 
to basal keratinocytes, as in wild-type mice, but also present in suprabasal layers, typical of 
human psoriasis. Expression of Keratin-1 (an indicator of early keratinocyte differentiation), 
which was localized in the suprabasal layer of wild-type mice, is increased and expressed 
throughout the epidermis in Card14∆E138+/– mouse skin. Card14∆E138 homozygous mice 
displayed development abnormalities (Supplementary Fig. 4a) and increased mortality. 
Surviving neonates were runts (Supplementary Fig. 4b) and died shortly after a few days, 
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typically with a very marked psoriatic phenotype (Supplementary Fig. 4c, d). Toluidine blue 
staining was performed to determine whether neonates had a skin barrier defect and an 
increase in skin permeability. Toluidine blue dye failed to stain the epidermis indicating that 
neither homozygous nor heterozygous pups had an epidermal barrier defect (Supplementary 
Fig. 4e).  
CARD14 gain-of-function mutation in vivo results in a transcriptomic gene profile 
similar to human plaque psoriasis 
To obtain a comprehensive overview of the transcriptional signature of the inflammatory 
milieu driving disease pathogenesis in Card14∆E138+/– mice, RNA was extracted from ear 
tissue of 8-week-old mice and subjected to RNAseq analysis (Fig. 3a-c). Differentially 
Expressed Genes (DEGs) from psoriatic tissue of Card14∆E138+/– mice, included 
upregulated hyperproliferative keratins (Krt6a, Krt6b, Krt16), antimicrobial peptides 
including β-defensins (Defb3, Defb4, Defb14), S100 proteins (S100a7, S100a8, S100a9) and 
Lipocalin-2 (Lcn2) and mRNA encoding cytokines of the innate (IL-1α, IL-1β, IL-36α, IL-
36β, IL-36γ, IL-6 and IL-17C) and adaptive (IL-20, IL-22, IL-23p19, IL-17F) immune 
systems. IL-20 family member IL-19, a cytokine previously shown to be upregulated in serum 
and tissue from psoriasis patients and a key component of the IL-23/IL-17A axis, was one of 
the most highly upregulated cytokines. Interestingly, IL-19 was shown previously to be 
specifically expressed by keratinocytes and acts in an autocrine manner in synergy with IL-
17A, to further enhance induction of anti-bacterial S100 proteins (Romer et al., 2003, Witte et 
al., 2014). Upregulation of chemokines was also evident including Ccl20 and the neutrophil 
chemoattractants Cxcl1, Cxcl2, Cxcl3 and Cxcl5. This transcriptional signature likely also 
reflects secondary changes in dermal endothelial cells and infiltrating immune cells. 
Interestingly, IL-1 family cytokines including receptor antagonists, NOD2, Caspase-1, 
Caspase-4 and NLRP3 are all upregulated in Card14∆E138+/– psoriatic tissue indicating that 
this phenotype is very much dependent on autoinflammatory as well as autoimmunity 
networks. 
Psoriatic tissue from Card14∆E138+/– mice also showed high expression of early 
cornified envelope proteins including Involucrin (Ivl) and IL-17A-induced small proline rich 
proteins (Sprr2b, Sprr2d). The S100-interacting protein Fabp5 is also increased. Late 
cornified envelope proteins including Lce3b and Lce3d show high expression and the serine 
protease inhibitors Sepinb3a, Sepinb3c and Sepina9 are also highly upregulated. 
Downregulated DEGs included Keratin-2 and -24, Serpin3b and Serpin12. Interestingly, 
Filaggrin-2 was also downregulated, inversely correlating with Filaggrin-1 expression in this 
model. IL-38 (Ilf10), an anti-inflammatory cytokine that specifically inhibits IL-36 cytokines, 
was also downregulated in Card14∆E138+/– psoriatic tissue, suggesting that in psoriatic skin 
disease increased activity of IL-36 cytokines is likely additionally enhanced by decreased 
expression of this endogenous inhibitor. 
We performed pathway analysis and “Keratinization”, “Formation of the cornified 
envelope”, “Signaling by Interleukins” and “Antimicrobial peptides” were enriched functions 
amongst upregulated genes (Fig. 3c). Comparing transcriptome analysis from 
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Card14∆E138+/– mice to that of human plaque psoriasis available from the publications of Li 
et al. (GSE54456) and Keermann et al. (GSE6651) (Li et al., 2014) (Keermann et al., 2015), 
there is positive enrichment of upregulated genes with both human studies and negative 
enrichment of down-regulated genes (Fig. 3d). This correlation demonstrates that the 
transcriptional landscape induced by CARD14 gain-of-function mutation in vivo is typical of 
human plaque psoriasis.  
To further confirm transcriptomic data and to analyze the expression of pro-
inflammatory genes at the onset of macroscopic skin changes in Card14∆E138+/– mice, RNA 
was extracted from ear tissue of 5-week old Card14∆E138+/– mice and analyzed by qPCR. 
Expression of mRNA encoding the pro-inflammatory cytokines IL-36γ, IL-1β, IL-17C and 
IL-19 (Fig. 3e) was significantly higher in ear tissue of Card14∆E138+/– mice. Similar to 
human psoriatic skin, Card14∆E138+/– murine tissue showed strong and significantly 
increased expression of genes encoding the the S100 anti-microbial peptides, S100a7 and 
S100a8 (Fig. 3f), β-defensins, Defb3, Defb4 and Defb14 (Fig. 3g) and the chemokines Cxcl1, 
Cxcl2 and Ccl20 (Fig. 3h). Expression of Filaggrin-1 and Filaggrin-2 was also assessed and 
confirmed RNAseq data, with an increase in Filaggrin-1 (Flg) and a decrease in Filaggrin-2 
(Flg2) in psoriatic tissue (Fig. 3i). Interestingly, expression of Caspase-14, which mediates 
pro-filaggrin processing to form the cornified envelope, is also increased in Card14∆E138+/– 
psoriatic tissue (Fig. 3 a, b). Loss of Filaggrin-1 expression is associated with an epidermal 
barrier dysfunction, which grants microbes the means to invade the epidermis, as in atopic 
dermatitis (O'Regan et al., 2008). Robust expression of Filaggrin-1 in psoriatic tissue of 
Card14∆E138+/– mice is consistent with the lack of any barrier defect in these mice (Fig. 3j). 
 
The CARD14/Bcl10 signaling axis is hyperactive in primary keratinocytes from 
Card14∆E138+/– mice 
To determine whether the epidermal changes observed in Card14∆E138+/– mice were due to 
dysregulated CARD14 function, epidermal tissue from ear pinnae of wild-type and 
Card14∆E138+/– mice were stained for Bcl10 and CARD14 expression. Both molecules 
showed enhanced expression in the epidermis from Card14∆E138+/– mice compared to wild-
type (Fig. 4a). To further assess the CARD14/Bcl10 interaction in Card14∆E138+/– mice, 
primary keratinocytes were isolated from wild-type and Card14∆E138+/– mouse epidermis 
and cultured ex vivo. Murine keratinocytes were subject to lysis in Triton-X-100-containing 
lysis buffer and soluble and insoluble fractions subject to SDS-PAGE (Fig. 4b). CARD14 and 
Bcl10 showed increased expression in the insoluble fraction in Card14∆E138+/– -derived cells 
compared to wild-type control cells, which correlated with decreased expression in the 
soluble fraction. Additionally, Bcl10 and CARD14 showed increased interaction as 
determined by co-immunoprecipitation (Fig. 4c) and enhanced processing of Malt1 substrate 
protein RelB. Bcl10 expression was visualized by confocal microscopy and in primary 
keratinocytes from wild-type mice Bcl10 was expressed uniformly throughout the cytoplasm, 
however, in keratinocytes from Card14∆E138+/– mice Bcl10 was observed in discrete 
signalosome structures (Fig. 4d). To assess the downstream effects of this increased 
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interaction, transcript levels of pro-inflammatory molecules were assessed in keratinocytes 
isolated and cultured from WT and Card14∆E138+/– mouse epidermis by qPCR. Levels of 
mRNA encoding S100A7, IL-17C, IL-19 and IL-36γ were significantly increased in 
Card14∆E138+/– keratinocytes compared to wild-type cells (Fig. 4e).   
 
Neutralization of the Th17-polarising cytokine IL-23 p19 subunit attenuates disease 
symptoms 
We next characterized the immune infiltrate of the skin of Card14∆E138+/– mice. Psoriatic 
skin of Card14∆E138+/– mice harbors a pronounced infiltrate of CD45-positive leukocytes 
(Fig. 5a). This immune infiltrate is composed of increased numbers of neutrophils, myeloid 
antigen-presenting cells, γδ- and αβ-T cells, as compared to wild-type littermates (Fig. 5b, 
Supplementary Fig. 5). Th17 cells play a central role in psoriasis pathogenesis and IL-23 
maintains the differentiation of pathogenic Th17 cells, which secrete IL-17A and IL-22, two 
of the cytokines that mediate the inflammatory effects and hyperproliferation associated with 
human psoriasis (Cai et al., 2012). Indeed, protein levels of IL-17A and IL-22 were 
significantly increased in Card14∆E138+/– ear tissue of adult mice (Fig. 5c). IL-23p19, IL-
17A and IL-22-encoding transcripts were also seen at significantly higher levels in 5-week 
old Card14∆E138+/– mouse skin (Fig. 5d). Similarly, the Th1 cytokines IFNγ and TNFα were 
also significantly elevated in ear tissue of 5-week old Card14∆E138+/– mice (Fig. 5e) 
contributing to an inflammatory milieu typical of human psoriasis.  
To assess whether CARD14-induced psoriatic disease symptoms can be attenuated in 
vivo by targeted disruption of the IL-23/Th17 axis, Card14∆E138+/– heterozygous mice were 
treated with a neutralizing antibody specific for the murine IL-23p19 subunit by 
intraperitoneal injection over the course of 15 days, while control mice were administered an 
IgG isotype antibody. Mice receiving anti-IL-23p19-neutralizing antibody showed a 
significantly decreased psoriatic phenotype on the ears and tail after 2 weeks of therapy (Fig. 
5f), and a significant reduction in ear thickness in comparison to the onset of treatment, and 
compared to IgG control animals (Fig. 5g). Further reductions were evident after 
administration of IL-23p19 over 3 weeks (Supplementary 6a-c). Histological features were 
assessed by Baker’s scoring system (Baker et al., 1992) and IL-23p19-treated mice showed a 
significant decrease in murine clinical score (Fig. 5h, i). In vivo blockade of IL-23p19 also 
reduced expression of mRNA encoding β-defensins, S100 proteins, IL-36γ and IL-19 (Fig. 
5j). These results indicate that disruption of the IL-23/Th17 immune signaling axis is 
sufficient to reverse the aberrant epidermal signaling networks induced by CARD14 GoF 
mutation. Thus, CARD14 GoF drives IL-23-mediated psoriatic skin disease and targeting of 
IL-23p19 in this mouse model is a rapid and effective therapeutic option, consistent with 
reports from phase III clinical trials in patients with plaque-type psoriasis (Nakamura et al., 
2017, Papp et al., 2017, Reich et al., 2017). 
 
DISCUSSION 
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Psoriasis is a common but complex inflammatory skin disease that arises from the interplay 
between stress or trauma within the epidermis and a dysregulated immune response. Genetic 
studies have revealed a role for selected genes particularly those of the innate and adaptive 
immune system and the IL-23/IL-17 signaling axis (Tsoi 2012). Interestingly, several genes 
encoding proteins in epithelial barrier function have also been linked to psoriasis 
susceptibility and GoF mutations in the gene encoding the keratinocyte signaling molecule, 
CARD14 have been associated with both psoriasis and PRP, though the extent to which 
CARD14 genetic variants contribute to disease susceptibility is currently unclear.  
Here, we unequivocally demonstrate that CARD14 gain-of-function alone is sufficient 
to drive disease pathogenesis in vivo and demonstrate that a single amino acid mutation of a 
key glutamic acid (E138) results in the complete immunological and clinical phenotype of 
plaque-type psoriasis in mice. The etiology of psoriasis has been elusive in the past, regarding 
the contribution of keratinocyte dysfunction versus altered immune function (Bos et al., 2005, 
Christophers 1996). However, our data strongly suggest that dysregulated keratinocyte 
signaling pathways initiated by CARD14 contribute to drive the pathogenic IL-23/IL-17 axis 
in vivo. Card14∆E138 heterozygous mice spontaneously and rapidly developed a chronic 
psoriatic phenotype with scaling skin lesions, epidermal acanthosis, parakeratosis and 
hyperkeratosis, keratinocyte hyperproliferation, and immune cell infiltration of lesional skin. 
In addition to Card14∆E138+/– tissue recapitulating the histological features of psoriasis, 
transcriptome profiling from affected skin in these mice correlated with upregulated and 
downregulated gene signatures observed in human plaque psoriasis. In particular high 
expression of anti-microbial peptides (β-defensins, S100 proteins), chemokines (Cxcl2, 
Ccl20) and cytokines (including IL-19, IL-36γ, IL-1β and IL-23p19) were observed. 
Additionally, neutralization of IL-23p19 significantly reduced skin lesions and the expression 
of anti-microbial peptides and pro-inflammatory cytokines in the skin of Card14∆E138 mice.  
Interestingly, Tanaka and colleagues recently demonstrated that CARD14-deficient 
mice were protected from developing imiquimod-induced psoriasiform disease (Tanaka et al., 
2018), which is consistent with our results that GoF mutation in CARD14 is sufficient to 
drive the complete immunopathogenesis of psoriatic disease in vivo. Interestingly, Tanaka’s 
study shows a role for CARD14-positive γδ T cells in imiquimod-induced psoriasiform 
disease. In our study, keratinocytes harboring mutant CARD14 contribute to disease 
pathogenesis, however, it will be of interest to further tease out the interplay of these different 
cell-types in disease pathogenesis. Taken together these reports place CARD14 in a central 
role of mediating psoriatic skin disease pathogenesis, which warrants further clinical 
appraisal. The physiological relevance to human disease means that the Card14∆E138+/– 
mouse model will become an invaluable tool for dissecting the complex signaling networks 
associated with psoriatic skin disease. This model will also be beneficial in the preclinical 
assessment of therapeutics aimed at specifically targeting molecular drivers of psoriasis and 
PRP in the future. These findings highlight the formation of the CARD14/Bcl10/Malt1 
complex as a key cellular process to target in the development of future therapies for psoriatic 
disease. Malt1-specific inhibitors have been suggested as a potential therapeutic strategy that 
can be employed for treating psoriatic skin disease, as inhibition of Malt1 function would 
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have the benefit of affecting T cell and keratinocyte function (downstream of CARD11 and 
CARD14, respectively) (Van Nuffel et al., 2017). Targeting CARD14 directly, however, may 
permit the development of more specific therapies with decreased side-effect profiles and 
merits further investigation into understanding CARD14 biology. 
 
MATERIALS AND METHODS 
Details of materials and methods are expanded in the Supplementary Information. 
 
Genetically Modified mouse strains 
To generate Card14∆E138 mice, C57BL/6J (JR 000664) oocytes were microinjected with 
Cas9 mRNA and donor DNA along with one of two guide RNA sequences. Two strains 
harboring the Card14∆E138 deletion were generated from separate founder animals, strain 
28900 (C57BL/6J-Card14em9(delE138)Lutzy/J) and 28882 (C57BL/6J-
Card14em5(delE138)Lutzy/J). Mouse strain 28900 was used for the experiments described 
within the manuscript. All animal experiments were performed in accordance with the 
regulations, guidelines and with ethical approval from the Cantonal Veterinary Office of 
Zürich, Switzerland.  
 
 
Cell culture 
Human primary keratinocytes were cultured as previously described (Feldmeyer et al., 2007). 
Briefly, human primary foreskin keratinocytes were passaged in keratinocyte serum free 
medium (Gibco BRL), supplemented with EGF and BPE (Gibco BRL) and seeded for 
experiments after 3 passages. All cells were maintained at 37 °C in a humidified atmosphere 
of 5% CO2. 
 
RNAseq transcriptome analysis 
RNA was extracted from whole ear tissue from 8 week-old female wild-type and 
Card14∆E138+/– mice. After librabry preparation, samples were analysed with the Illumina 
HiSeq 4000, which was used to generate single end reads of length 125nt. For data processing 
the raw reads were first cleaned by removing adapter sequences, trimming low quality ends, 
and filtering reads with low quality (phred quality <20) using Trimmomatic (Bolger et al., 
2014). Sequence alignment of the resulting high-quality reads to the Mus musculus reference 
genome (build GRCm38) and quantification of gene level expression was carried out using 
RSEM (Version 1.3.0) (Li and Dewey 2011). Differential expression was computed using the 
generalized linear model implemented in the Bioconductor package EdgeR (Version 3.20.1)  
(Robinson et al., 2010). The data was deposited in the European Nucleotide Archive 
(accession number PRJEB25394). Pathway analysis was performed using ReactomePA (Yu 
and He 2016). The top significant pathways were plotted as a dotplot. GSEA analysis was 
performed using fgsea (Sergushichev 2016) and datasets from GSE66511 and GSE54456 
were obtained from NCBI Gene Expression Omnibus (GEO).  
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FIGURE LEGENDS 
Figure 1 Mutation of Card14 E138 causes spontaneous signalosome assembly in primary 
keratinocytes and is dependent on a functional CARD domain. (a, b) Primary 
keratinocytes were transfected with Myc-tagged CARD14 WT, CARD14 E138A and (a) 
CARD14 ∆E138 or (b) CARD14 R38C/E138A for 24 h. Cell lysates were 
immunoprecipitated with an anti-Bcl10 antibody, followed by immunoblotting with indicated 
antibodies. (c) Human primary keratinocytes were transfected for 24 h with Myc-tagged 
CARD14 WT, CARD14 E138A or CARD14 R38C/E138A. Cells were lysed in Triton-X-
containing buffer and soluble and insoluble fractions were subject to SDS-PAGE followed by 
immunoblotting with indicated antibodies. (d) Human primary keratinocytes were transfected 
for 24 h with Myc-tagged CARD14 WT, CARD14 E138A, CARD14 ∆E138 or CARD14 
R38C/E138A and visualized for expression and localization by confocal microscopy using 
specific anti-Myc and anti-Bcl10 antibodies. Nuclei were stained with DAPI. Scale bar = 15 
µm. (e) Flow cytometry analysis and immunoblot analysis of HEK293T cells transfected with 
increasing amounts of Myc-tagged CARD14 constructs with Strep-tagged Malt1 and the 
EYFP-LVSR-eCFP reporter plasmid for 24 h. (f) Human primary keratinocytes were 
transfected for 24 h with Myc-tagged CARD14 constructs. Cell lysates were subject to 
immunoblotting with anti-Myc, anti-IL-36γ and anti-β-actin antibodies. Data are (a-f) 
representative of three independent experiments  
Figure 2 Card14∆E138+/– heterozygous mice develop a spontaneous psoriatic phenotype. 
(a) 8 week-old Card14∆E138+/– heterozygous mice develop dry skin around the eyes and 
whiskers and dry flaky skin on the ears and tail. (b) Ear thickness (mm) of Card14∆E138+/– 
and wild-type littermates measured with microcalipers (n=9 per group). (c) Card14∆E138+/– 
mice and wild-type littermates were weighed (g) at 8-weeks old (n=8 per group). (d - f, h) 
H&E staining of ear sections from 8 week-old Card14∆E138+/– and wild-type mice. Arrows 
show (e) parakeratosis (arrow), orthokeratosis (arrowhead), (f) microabscess, (h) blood 
vessels. Scale bar = (d) 300 or (e, f, h) 100 µm. (g) Ear sections from 8 week-old 
Card14∆E138+/– mice stained with a specific anti-Ly6G antibody or isotype control. Scale bar 
= 100 µm. (i – k) Ear sections from 8 week-old Card14∆E138+/– and wild-type littermates 
were stained with specific antibodies against (i) Ki67, Keratin-14 and Keratin-1. Pictures are 
representative of all Card14∆E138+/– heterozygous mice observed (a) or are representative of 
8 individual mice per group (d - i), or each data point represents an individual mouse (b, c) 
and subjected to a two-tailed unpaired Student’s t-test, **** P<0.0001. ns, non-significant. 
 
Figure 3 Transcriptome analysis of psoriatic tissue from ears of Card14∆E138+/– mice 
reveals a gene signature typical of human plaque psoriasis. (a-d) RNA was extracted from 
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8 week-old Card14∆E138+/– heterozygous mice and wild-type littermates and subject to 
RNAseq analysis. (a) Heatmap showing the 542 genes differentially expressed genes (DEGs) 
between 3 replicates of Card14∆E138+/– heterozygous mice and wild-type littermates. (b) 
Volcano plot showing the threshold for significant genes from Card14∆E138+/– versus wild-
type mice. A threshold of FDR < 0.05 and Log2 Ratio > 2 or < -2 was chosen. DEGs of 
particular interest are labeled. (c) Dotplot showing the significantly enriched pathways from 
the Reactome. Each dotsize represents the overlap between the pathway and the gene set. The 
color represents the p value. (d) Gene Set Enrichment Analysis (GSEA) enrichment plots 
comparing transcriptome data from Card14∆E138+/– mice with online published data from 
human plaque psoriasis patients, GSE66511 and GSE54456. Normalized enrichment score 
(NES) and adjusted p value (padj) are indicated. (e - i) RNA was extracted from whole ear 
tissue of 5-week old mice and subjected to qPCR analysis to measure mRNA expression 
levels of (e) Il1f9 (IL-36γ), Il1b, Il17c, Il19, (f) S100a7, S100a8, (g) Defb3, Defb4, Defb14, 
(h) Cxcl1, Cxcl2, Ccl20, (i) Flg and Flg2. (j) Ear sections from 8 week-old Card14∆E138+/– 
and wild-type littermates were stained with a specific antibody against Filaggrin-1 or isotype 
control. Black scale bar = 100 µm, grey scale bar = 50 µm. (a - d) Analysis of one experiment 
with 3 mice per group, (e - i) are representative of two independent experiments with 7 or 8 
mice per group (total n=15) and data were subjected to a two-tailed unpaired Student’s t-test. 
*P<0.05, **P<0.01, ***P<0.001, **** P<0.0001. (j) is representative of 8 individual mice 
per group.  
  
Figure 4 Keratinocytes from Card14∆E138+/– mice display enhanced CARD14/Bcl10 
activity. (a) confocal microscopy analysis of epidermal tissue from ear pinnae from WT and 
Card14∆E138+/– mice stained for specific anti-Bcl10, -CARD14 or isotype control antibodies. 
Nuclei were stained with DAPI. Scale bar = 50 µm. (b - e) Primary murine keratinocytes were 
isolated from WT and Card14∆E138+/–  tail epidermis and cultured ex vivo for 3-4 days. (b) 
Cells were lysed in Triton-X-containing buffer and soluble and insoluble fractions were 
subject to SDS-PAGE followed by immunoblotting with indicated antibodies. (c) Cell lysates 
were immunoprecipitated with an anti-Bcl10 antibody, followed by immunoblotting with 
indicated antibodies. ∆E = keratinocytes from Card14∆E138+/– mice. (d) Cells visualized for 
expression and localization of endogenous murine Bcl10 by confocal microscopy using a 
specific anti-Bcl10 antibody. Nuclei were stained with DAPI. Scale bar = 15 µm. (e) RNA 
was extracted from whole ear tissue of 5-week old mice and subjected to qPCR analysis of 
mRNA expression of S100a7, Il17c, Il19 and Il1f9 (IL-36γ). Images are representaive of (a-d) 
three independent experiments or (e) data are presented as the the mean ±s.e.m of three 
independent experiments and were subjected to a two-tailed unpaired Student’s t-test.  
*P<0.05, **P<0.01. 
 
Figure 5 Immune cell infiltrate shows a Th17 signature and IL-23p19 neutralization 
ameliorates the phenotype in Card14∆E138+/– mice. (a-b) Flow cytometry analysis of 
single cell suspension from ear tissue from age- and sex-matched adult Card14∆E138+/– mice 
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and littermate controls. Shown are the number of (a) CD45+ hematopoietic cells, (b) 
neutrophils (CD11b+Ly6G+), inflammatory (CD11b+Ly6G–NK1.1–MHCIIhiLy6Chi) and non-
inflammatory (CD11b+Ly6G–NK1.1–MHCIIhiLy6C–) antigen-presenting cells (APCs), αβ T 
cells (CD3lowTCRβ+) and γδ T cells (CD3lowTCRβ–) per ear. (c) Whole ears from age- and 
sex-matched adult Card14∆E138+/– and wild-type mice were homogenized and analyzed for 
IL-17A and IL-22 protein levels by ELISA (n=8). (d, e) RNA was extracted from whole ear 
tissue of 5-week old mice and subjected to qPCR analysis of (d) Il23p19, Il17a and Il22 or (e) 
Ifng (IFNγ), Tnfa  mRNA expression levels. (f) Macroscopic images of ears and tails of IgG- 
and IL-23p19-treated mice at the beginning and end (day 15) of the experiment. (g) Ear 
thickness of IL-23p19-treated animals and control animals at days 0, 6, 10 and 15 of the 
experiment (IL-23p19 group n=6, IgG group n=6). (h) Representative histological features 
shown by H&E staining at Day 15. Scale bar = 500 µm (i) Clinical scoring of histological 
features of IgG- versuse IL-23p19-treated mice. (j) qPCR analysis of mRNA expression of 
Defb4, S100a8, Il1f9 (IL-36γ) and Il19 in ear tissue from IL-23p19-treated and IgG-treated 
mice. (a, b) Data are representative of three independent experiments or (c) is one experiment 
with 8 - 9 mice per group or (d, e) are representative of two independent experiments with 7 
or 8 mice per group (total n=15). (f) Images are representaive of IgG- and IL-23p19-treated 
mice (total n=10 per group) or (g - j) data are presented as the the mean ±s.e.m of 6 mice, 
representative of two independent experiments (total n=10 per group) and were subjected to a 
two-tailed unpaired Student’s t-test.  *P<0.05, **P<0.01, ***P<0.001, **** P<0.0001.  
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